Back

Are sodium-glucose co-transporter 2 inhibitors safe in hypertrophic cardiomyopathy?

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 9 Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Viktoriia Biletska

V.N. Karazin Kharkiv National University, Kharkiv (Ukraine)

6 More presentations in this session

Presentation thumbnail
Genetic testing in hypertrophic cardiomyopathy: for all or just selected patients?
Doctor A. Fonseca Vazao (Leiria, PT)
Abstract Slides Video
Presentation thumbnail
Hypertrophic cardiomyopathy phenotype and the importance of systemic inflammation
Doctor I. Miranda (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Could we use cardiopulmonary exercise test to distinguish hypertrophic cardiomyopathy from Fabry disease? New insights from Italy
Doctor F. Re (Roma, IT)
Abstract Slides Video
Presentation thumbnail
Design of ODYSSEY-HCM: a phase 3 randomized placebo-controlled study to assess the efficacy and safety of mavacamten in patients with nonobstructive hypertrophic cardiomyopathy
Doctor I. Olivotto (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Is the mortality of chronic chagas cardiomyopathy higher than cardiomyopathy due to other etiologies? A systematic review and meta-analysis
Doctor L. Echeverria (Floridablanca, CO)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 9

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Real-world insights into mavacamten use for obstructive hypertrophic cardiomyopathy: symptomatic improvement before gradient reduction?
thumbnail
Congress Presentation
Different exercise hemodynamic profiles in obstructive and nonobstructive hypertrophic cardiomyopathy: importance of unmasking diastolic dysfunction
thumbnail
Congress Presentation
Efficacy and safety of sotagliflozin in patients with symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy (SONATA-HCM): study design

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources